Ara
Toplam kayıt 20, listelenen: 11-20
Magnet dislocation during 3 T magnetic resonance imaging in a pediatric case with cochlear implant
(Assoc Brasileira Otorrinolaringologia & Cirurgia Cervicofacial, 2019)
[No abstract available]
Occupational risks and safety precautions for COVID-19 in workers with rheumatic diseases
(Lippincott Williams & Wilkins, 2020)
Coronavirus disease 2019 (COVID-19) has spread worldwide rapidly and was declared a pandemic on March 11, 2020, by the World Health Organization.
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
(Wiley, 2023)
The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese.
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' reply
(Wiley, 2023)
We appreciate the editorial comments by Drs. Sun and Fan about our study assessing the associations of patient-reported outcomes (PROs) and non-invasive tests (NITs) in patients with non-alcoholic fatty liver disease (NAFLD) ...
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
(Kare Publishing, 2023)
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
The heated debate over NAFLD renaming: An ongoing saga
(Kare Publishing, 2023)
In 1980, Jurgen Ludwig, a pathologist at the Mayo Clinic, and colleagues formally described a disorder that involved the accumulation
of fat in the liver, independent of significant alcohol consumption, or
other secondary ...
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
(Kare Publishing, 2024)
The term metabolic dysfunction-associated steatotic liver disease
(MASLD), which evolved from its predecessor, nonalcoholic fatty liver
disease (NAFLD),[1]
Metabologenomics and network pharmacology to understand the molecular mechanism of cancer research
(Baishideng Publishing Group Inc. Tutar Y. Metabologenomics and network pharmacology to understand the molecular mechanism of cancer research. World J Clin Cases 2024; 12(3): 474-478 [PMID: 38322468 DOI: 10.12998/wjcc.v12.i3.474], 2024)
In this editorial I comment on the article "Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer" published in the recent issue of the World Journal of Clinical Cases ...
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?
(Lippincott Williams and Wilkins, 2024)
....